Y-mAbs Therapeutics Inc
NASDAQ:YMAB

Watchlist Manager
Y-mAbs Therapeutics Inc Logo
Y-mAbs Therapeutics Inc
NASDAQ:YMAB
Watchlist
Price: 8.53 USD 0.12% Market Closed
Market Cap: 216.8m USD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Loading...
Revenue
Loading...
Operating Income
Loading...
Net Income
Loading...

Wall Street
Price Targets

YMAB Price Targets Summary
Y-mAbs Therapeutics Inc

Wall Street analysts forecast YMAB stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for YMAB is 8.2 USD with a low forecast of 3.03 USD and a high forecast of 9.03 USD.

YMAB Lowest Forecast
Wall Street Target
3.03 USD
64% Downside
YMAB Average Forecast
Wall Street Target
8.2 USD
4% Downside
YMAB Highest Forecast
Wall Street Target
9.03 USD
6% Upside
Lowest
Price Target
3.03 USD
64% Downside
Average
Price Target
8.2 USD
4% Downside
Highest
Price Target
9.03 USD
6% Upside
Y-mAbs Therapeutics Inc Competitors:
Price Targets
Y
002675
Yantai Dongcheng Biochemicals Co Ltd
4% Downside
300294
China Resources Boya Bio pharmaceutical Group Co Ltd
25% Upside
A
AREC
Arecor Therapeutics PLC
304% Upside
ASMB
Assembly Biosciences Inc
37% Upside
Y
002675
Yantai Dongcheng Biochemicals Co Ltd
4% Downside
300294
China Resources Boya Bio pharmaceutical Group Co Ltd
25% Upside
A
AREC
Arecor Therapeutics PLC
304% Upside
ASMB
Assembly Biosciences Inc
37% Upside
REGN
Regeneron Pharmaceuticals Inc
26% Upside
IFRX
InflaRx NV
375% Upside
PRQR
ProQR Therapeutics NV
301% Upside
ALGEN
Genoway SA
96% Upside

Revenue
Forecast

Revenue Estimate
Y-mAbs Therapeutics Inc

The compound annual growth rate of Y-mAbs Therapeutics Inc's revenue for the next 3 years is 8%.

N/A
Past Growth
8%
Estimated Growth
Estimates Accuracy
1%
Average Beat
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Y-mAbs Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-4%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Y-mAbs Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-22%
Average Miss
What are analyst estimates?

See Also

Summary
YMAB intrinsic value, competitors valuation, and company profile.
DCF Valuation
YMAB stock valuation using Discount Cash Flow valuation method.
Relative Valuation
YMAB stock valuation using valuation multiples.
Wall Street Estimates
YMAB price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
YMAB stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is YMAB's stock price target?
Price Target
8.2 USD

According to Wall Street analysts, the average 1-year price target for YMAB is 8.2 USD with a low forecast of 3.03 USD and a high forecast of 9.03 USD.

What is Y-mAbs Therapeutics Inc's Revenue forecast?
Projected CAGR
8%

The compound annual growth rate of Y-mAbs Therapeutics Inc's revenue for the next 3 years is 8%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 277,000+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.